ImageneBio, Inc. Cash Flow Conversion Efficiency
ImageneBio, Inc. cash flow conversion efficiency. Based on the latest financial reports, ImageneBio, Inc. (IMA) has a cash flow conversion efficiency ratio of -0.064x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.07 Million) by net assets ($142.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ImageneBio, Inc. (2018–2025)
Cash flow conversion efficiency of ImageneBio, Inc. from 2018 to 2025. This chart illustrates how ImageneBio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View ImageneBio, Inc. stock price for real-time trading data and today's change.
ImageneBio, Inc. Cash Flow Conversion Ratio Explained
ImageneBio, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ImageneBio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImageneBio, Inc. ranked by their cash flow conversion efficiency. Also see ImageneBio, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deswell Industries Inc
NASDAQ:DSWL
|
0.027x |
|
I-Hwa Industrial Co Ltd
TW:1456
|
-0.042x |
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
-0.384x |
|
Hyundai Industrial Co. Ltd
KQ:170030
|
-0.005x |
|
PS Tec. Co. Ltd
KQ:002230
|
0.036x |
|
Fission 3.0 Corp
V:FUU
|
-0.019x |
|
The LEADCORP Inc
KQ:012700
|
-0.043x |
|
Centara Hotels & Resorts Leasehold Property Fund
BK:CTARAF
|
0.025x |
Annual Cash Flow Conversion Efficiency for ImageneBio, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of ImageneBio, Inc. from 2018 to 2025. Review cash generation quality of ImageneBio, Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $133.14 Million | $-47.84 Million | -0.359x | +1.63% |
| 2024-12-31 | $125.93 Million | $-46.00 Million | -0.365x | +22.23% |
| 2023-12-31 | $169.76 Million | $-79.74 Million | -0.470x | +6.84% |
| 2022-12-31 | $146.97 Million | $-74.11 Million | -0.504x | -73.97% |
| 2021-12-31 | $207.88 Million | $-60.25 Million | -0.290x | -177.43% |
| 2020-12-31 | $-101.05 Million | $-37.83 Million | 0.374x | +148.01% |
| 2019-12-31 | $-61.46 Million | $47.93 Million | -0.780x | -407.93% |
| 2018-12-31 | $-45.84 Million | $-11.61 Million | 0.253x | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more